Revolution Medicines and Iambic Therapeutics have partnered in a multi-year collaboration to harness AI technology for cancer drug discovery. Iambic will train its NeuralPLexer AI model using Revolution’s data, aiming to identify novel drug candidates against challenging oncology targets. Each party retains rights to select exclusive targets. This alliance builds on recent trends leveraging AI platforms for scalable biomolecular interaction predictions. Similar partnerships, including ones involving Lundbeck in neurological diseases, underscore AI’s ascending role in preclinical drug discovery and optimization.